



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel : 022-2407 2249 / 2401 9025 (30 Lines)
Fax.: 022-2407 3462 / 2407 0144
Email: finacc@aartidrugs.com
website: www.aartidrugs.com
CIN No.:L37060MH1984PLC055433

Ref. No.: ADL/SE/2018-2019

Date: 16th May, 2018

To,
Department of Corporate Service,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400 001,
Maharashtra
BSE CODE - 524348
BSE ID - AARTIDRUGS

To,
National Stock Exchange of India Limited,
"Exchange Plaza", Bandra - Kurla Complex,
Bandra (E), Mumbai - 400051,
Maharashtra
NSE SYMBOL: AARTIDRUGS

Dear Sir/Madam,

Please find enclosed herewith copy of the press release issued by the Company on 16th May, 2018.

This is for your information and records.

Thanking you,

Yours faithfully,
For Aarti Drugs Limited

Vibhav S. Ranade
Company Secretary & Compliance Officer





Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel .: 022-2407 2249 / 2401 9025 (30 Lines)
Fax.: 022-2407 3462 / 2407 0144
Email: finacc@aartidrugs.com
website: www.aartidrugs.com
CIN No.:L37060MH1984PLC055433

Press release for Mar'18:

March quarter has shown good demand growth in API market, with a value growth of around 16.8%, whereas consolidated sales grew by 10.6%. Volume growth of about 8% in API market was a major contributing factor for revenue growth along with increase in selling prices.

Consolidated EBITDA for the quarter ended Mar'18 is 57.38 crores, up by 18.2% and Consolidated Profit after tax for the quarter ended Mar'18 is 23.99 crores, up by 9.2%. Operating margins are very good due to lower raw material costs and better operational efficiency. Company will be focusing on reduction of inventories in coming quarter to further reduce working capital. Company successfully completed share buyback in Mar quarter and still was able to reduce Debt/Equity ratio to 1.19 as of Mar'18.

Company will be submitting final response to USFDA by the end of Jun'18 quarter for the latest re-inspection, which took place in Dec'17. Europe and Southeast Asia will continue to be key growth drivers for the company in exports. Company started with the commercial operations in its recently commissioned multipurpose facility in Tarapur, which is ultimately intended for the API exports to European markets. As of date, Company also resumed the production of all the three products that were affected in the unfortunate accident, which occurred in the neighboring plant of Novaphene Specialities Pvt. Ltd in the month of Mar'18.

For Aarti Drugs Limited

Harshit M. Savla
Jt. Managing Director

